Theravance Faces Prospect Of Another Trial For Vibativ In Hospital-Acquired Pneumonia
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA says if it accepts pooling of mortality data from the drug's two nosocomial pneumonia studies, they would be considered a single trial.